Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)

Cogent Biosciences' Current Deferred Revenue history spans 4 years, with the latest figure at $312000.0 for Q2 2020.

  • Quarterly Current Deferred Revenue fell 97.94% to $312000.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $312000.0 through Jun 2020, down 97.94% year-over-year, with the annual reading at $1.3 million for FY2019, 92.67% down from the prior year.
  • Current Deferred Revenue came in at $312000.0 for Q2 2020, down from $841000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $20.4 million in Q2 2018 to a low of $312000.0 in Q2 2020.
  • The 4-year median for Current Deferred Revenue is $15.2 million (2019), against an average of $12.0 million.
  • Year-over-year, Current Deferred Revenue soared 160.47% in 2018 and then crashed 97.94% in 2020.
  • Cogent Biosciences' Current Deferred Revenue stood at $6.9 million in 2017, then skyrocketed by 160.47% to $17.9 million in 2018, then crashed by 92.67% to $1.3 million in 2019, then tumbled by 76.27% to $312000.0 in 2020.
  • Per Business Quant, the three most recent readings for COGT's Current Deferred Revenue are $312000.0 (Q2 2020), $841000.0 (Q1 2020), and $1.3 million (Q4 2019).